window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'UA-108383172-1');

Novigenix Wins the 2021 Felix Burda Award in Medicine & Science

By |2024-06-17T20:38:55+02:0022 July 2021|Communiqué de presse, News Novigenix|

 Novigenix Wins the 2021 Felix Burda Award in Medicine & Science  • Category ‘Innovation in Immuno-Transcriptomics for Early Detection of Colorectal Cancer’  • Award recognizes excellence in innovation and impact in early detection of cancer  LAUSANNE, SWITZERLAND - July 22, 2021 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision

Novigenix-Led Consortium Secures Eurostars Funding to Develop Predictive Immune Checkpoint Inhibitor Test

By |2024-06-17T20:40:00+02:0022 December 2020|Communiqué de presse, News Novigenix|

Total amount up to €1 million awarded to consortium of leading cancer centers and innovative healthcare companies LAUSANNE, SWITZERLAND – 07:00 CET, December 22, 2020 Novigenix SA Switzerland, a pioneer in Immuno-Transcriptomics for precision medicine today announced that a consortium, including PamGene International BV and Radboud University (The Netherlands), has been awarded a grant up to €1 million

Novigenix presents new Immuno-Transcriptomic data for prediction of response to immunotherapy in metastatic urothelial cancer patients

By |2024-06-17T20:40:57+02:0024 September 2020|Communiqué de presse, News Novigenix|

Newly discovered blood signature presented at ESMO 2020  LAUSANNE, SWITZERLAND – 07:00 CET, September 17th, 2020 – Novigenix SA, a pioneer in Immuno-Transcriptomics for precision oncology, today announced a new Immuno-Transcriptomic signature for predicting response to immunotherapy in metastatic urothelial cancer patients. The data are presented at the European Society for Medical Oncology (ESMO)

Novigenix-Led Consortium Secures Eurostars Funding to Develop Multi-Omics Test for Colon Cancer Detection and Monitoring

By |2024-06-17T20:25:03+02:0021 January 2020|Communiqué de presse, News Novigenix|

Total amount up to €1 million awarded to consortium of leading cancer centers and innovative healthcare companies   LAUSANNE, SWITZERLAND - 07:00 CET, January 21, 2020 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced that a consortium, including Maastricht University (The Netherlands),

Novigenix Develops New NGS-based Immune Cell Type Specific RNA Signatures for Early Colon Cancer Detection

By |2024-06-17T20:26:31+02:0011 December 2019|Communiqué de presse, News Novigenix|

Immune cell type specific profiles correlate with traditional blood cell count method LAUSANNE, SWITZERLAND - 07:00 CET, December 11, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced the development of a new immune cell type specific Immuno-Transcriptomic signature for the detection

Novigenix and RadioMedix to Develop Neuroendocrine Cancer Precision Diagnostic Test

By |2024-06-17T20:43:09+02:0014 October 2019|Communiqué de presse, News Novigenix|

Test to measure response to radiopharmaceutical therapy LAUSANNE, SWITZERLAND - 07:00 CET, October 14, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced a collaboration agreement with RadioMedix Inc., a radiopharmaceutical company, to develop a precision diagnostic test based on Novigenix’s technology.

Novigenix Receives Reimbursement Coverage for Colox® in Switzerland

By |2024-06-17T20:27:22+02:009 October 2019|Communiqué de presse, Medical information, News Novigenix|

First liquid biopsy test reimbursed in Switzerland for colon cancer screening through private outpatient supplementary insurance product offered by Helsana LAUSANNE, SWITZERLAND - 07:00 CET, October  9, 2019  - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine. today announced that Helsana, the leading health insurance

Novigenix’s New Early Colon Cancer Detection Blood Test Demonstrates Positive Results

By |2024-06-17T20:27:48+02:0030 September 2019|Communiqué de presse, News Novigenix|

Data on test’s newly discovered blood signature presented at ESMO 2019 LAUSANNE, SWITZERLAND - 07:00 CET, September 30, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced promising data from a study of a new Immuno-Transcriptomic signature for early detection of colorectal

Novigenix to Present Data on New Molecular Signature for Early Detection of Colon Cancer at ESMO 2019

By |2024-06-17T20:49:40+02:0010 September 2019|Communiqué de presse, News Novigenix|

Company Launches New Website to Enhance New Strategy Company to present at the Convergence of Oncology meeting in Lausanne LAUSANNE, SWITZERLAND - 07:00 CET, September 10, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced the discovery of a new molecular signature

Novigenix Strengthens Board with Appointment of Francois Martelet, M.D. Non-Executive Director

By |2024-06-17T20:45:20+02:0018 June 2019|Communiqué de presse, News Novigenix|

LAUSANNE, SWITZERLAND - 07:00 CET, June 18, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes products for early cancer detection and precision medicine today announced the appointment of Francois Martelet, M.D. to its Board of Directors as a non-executive director. Dr. Martelet has over 25 years’ experience at both corporate and operational

Go to Top